Study S001435

Evaluating the Effect of Hemodialysis Modality and New Anti-glycemic Drugs on NETosis on in Hemodialysis and Diabetic Patient, and Assessment of NETosis in Various Kidney Diseases

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06821919
Acronym: NETs
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 70
Start: 2024-05-13
Primary completion: 2030-12-30
Lead sponsor: Western Galilee Hospital-Nahariya
Conditions: Diabetes Mellitus; Kidney Disease
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

NETosis marker- citrullinated histone H3 (citH3) [Before treatment, 1,2 , 3, 6 and 12 months after starting anti-diabetic drugs or immunosuppression]
NETosis marker- Myeloperoxidase [Before treatment, 1,2,3,6 and12 moths after treatment.]
NETosis marker- Neutrophil elastase (NE) [Before treatment, 1,2 , 3, 6 and 12 months after starting anti-diabetic drugs or immunosuppression]
NETosis marker: Peptidylarginine deiminase 4-PAD4 [Before treatment, 1,2 , 3, 6 and 12 months after starting anti-diabetic drugs or immunosuppression]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.